Agreed.
The industry is watching - Mesoblast won the Fierce Biotech Innovation Award for Remestemcel-L after all!
In terms of the Accelerated Approval, I hope that this ends up being a win-win-win-win situation for all concerned.
1. FDA gets to play tough guys & keep the hurdle high for MSC
2. Mesoblast gets conditional approval
3. Patients get treated
4. SHs get rewarded
Bring on the Type A request & meeting!
Hang in there MSB'ers and HODL.
Ann: Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment, page-133
-
- There are more pages in this discussion • 313 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
-0.030(2.03%) |
Mkt cap ! $1.655B | |||
| Open | High | Low | Value | Volume |
| $1.48 | $1.51 | $1.43 | $6.613M | 4.498M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2482 | $1.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 27045 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |